Beta-blocker and other analogous treatments that affect bone mass and sympathetic nerve activity in ovariectomized rats.
We investigated whether treatments with beta-blockers or other administrations that have similar actions to beta-blockers, such as Chinese herbs or needling, were effective in treating osteoporosis induced by ovariectomy (OVX). Female Wister rats were divided into five groups: a sham-operated control group treated with vehicle (Sham, n = 8), an ovariectomized (OVX) group treated with vehicle (Model, n = 8), an OVX group administered with propranolol (Pro, n = 10), an OVX group administered an ethanol extract of Fructus Citri Sarcodactylis (Fcs, n = 9), and an OVX punctured at Sanyinjiao (SP-6) and Neiguan (PC-6) (Needling, n = 8). The treatment started when rats were 12 weeks old and continued for 24 weeks. Serum osteocalcin and urinary deoxypyridinoline (Dpd) levels were upregulated in rats in response to OVX, together with a significantly decreased BMD and trabecular bone area. The Pro, Fcs and Needling treatment improved the decreased BMD and the trabecular area, increased the trabecular number, lowered the trabecular separation to some extent as well as significantly depressed the urinary Dpd levels (p < 0.05). The bone formation markers, such as the mineralizing surface, mineral apposition rate and bone formation rate were not significantly changed, along with a slightly higher trend of osteocalcin levels when compared with the Model rats. The slower heart rate and lower plasma NE levels in these therapeutic groups were also found. Our results suggested that propranolol, Fcs and needling on Sanyinjiao (SP-6) and Neiguan (PC-6) may improve the bone mass of OVX rats, and it provides an alternative and potential therapy for the prevention of postmenopausal osteoporosis.
Zhang
Wenping
W
Acupuncture Department, Suzuka University of Medical Science, Mie, Japan.
Kanehara
Masayuki
M
Zhang
Yanjun
Y
Wang
Xiaoming
X
Ishida
Torao
T
D015670:Acupuncture Therapy / Q000379:methods*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D015519:Bone Density / Q000187:drug effects / Q000502:physiology*; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D031263:Elaeagnaceae; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D009638:Norepinephrine / Q000097:blood; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D010052:Ovariectomy / Q000009:adverse effects; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
D000319:Adrenergic beta-Antagonists; D010936:Plant Extracts; D015675:Osteocalcin; D011433:Propranolol; D009638:Norepinephrine